• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Applied NeuroSolutions Founding Scientist, Dr. Peter Davies, Featured in New York Times Article on Alzheimer's Disease

Posted on: Monday, 11 June 2007, 12:00 CDT

Applied NeuroSolutions, Inc. (OTC BB:APNS)(www.appliedneurosolutions.com) a Company focused on the development of an integrated product portfolio for the treatment and diagnosis of Alzheimer's disease (AD), today announced it's long-standing founding scientist, Dr. Peter Davies, a world renowned expert on AD research, was interviewed in a feature article entitled "Taking On Alzheimer's" in the New York Times on June 10, 2007, indicating his novel approach to AD therapeutics is being developed in a collaboration between APNS and Eli Lilly and Company (NYSE: LLY).

Dr. Davies, the Judith and Burton P. Resnick Professor of Alzheimer's Disease Research at the Albert Einstein College of Medicine, highlighted issues with much of the current Alzheimer's drug development. Dr. Davies also discussed the alternative theories he has been working on over his 30 year career, focusing on AD solutions. Dr. Davies approach, as well as the tools developed with the scientists at APNS, were key components of the interest of large pharma companies, that ultimately culminated in a collaboration agreement with Eli Lilly and Company to develop therapeutics to treat Alzheimer's disease.

For the complete article, visit the New York Times website at www.nytimes.com.

About Applied NeuroSolutions:

Applied NeuroSolutions, Inc. (OTC BB:APNS) is developing, in collaboration with Eli Lilly and Company, novel therapeutic compounds to treat and diagnostics to detect Alzheimer's disease (AD) based on discoveries originating from the Albert Einstein College of Medicine. Applied NeuroSolutions has discovered biomarkers that the company believes will aid in the development of effective AD treatments. Applied NeuroSolutions has also been working on both a cerebrospinal fluid (CSF) diagnostic test and blood tests to detect AD at a very early stage. The CSF test can already differentiate AD patients from those with other diseases that have similar symptoms. There is currently no FDA approved diagnostic test to detect Alzheimer's disease. Alzheimer's disease currently afflicts over 5 million Americans, and the world market for AD therapy is currently estimated to be 30 million patients. For more information, visit www.appliedneurosolutions.com.

This press release contains forward-looking statements about Applied NeuroSolutions. The company wishes to caution the readers of this press release that actual results may differ from those discussed in the forward-looking statements and may be adversely affected by, among other things, the risks associated with new product development and commercialization, clinical trials, intellectual property, regulatory approvals, potential competitive offerings, and access to capital. For further information, please visit the company's website at www.appliedneurosolutions.com, and review the company's filings with the Securities and Exchange Commission.

Source: Business Wire

More News in this Category